CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
- To understand and address, through clinical and translational research, the disease burden associated with genitourinary malignancies (advanced and superficial bladder) in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.
- To update, review, and discuss recent results of clinical studies conducted by the Canadian Cancer Trials Group and/or by national/international collaborators.
- To provide mentoring opportunities for investigators new to clinical trial research.
- To understand and apply new clinical trial methodologies in the field of clinical research related to genitourinary malignancies.

7:00 am Welcome

CCTG Lead Closed TRIALS

7:05 am BL.12 A Phase II Randomized trial of Nab-Paclitaxel vs. Paclitaxel in Second Line Metastatic Urothelial Carcinoma K. Sridhar

7:10 am BLC.4 (SWOG S1605): Phase II Trial of Atezolizumab (NSC #783608) in BCG- Unresponsive Non-Muscle Invasive Bladder Cancer. W. Kassouf

CCTG InterGroup CLOSED TRIALS

7:20 am BLC.1/SWOG S1011 Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at the Time of Radical Cystectomy For Muscle Invasive Urothelial Cancer W. Kassouf

CCTG InterGroup APPROVED TRIALS

7:25 am BLC.2 (Alliance A031501): Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) versus Placebo. K. Sridhar

7:35 am BLC.3 (SWOG S1602): A Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer. W. Kassouf
TRIAL PROPOSAL UPDATES

7:45 am  A Randomized PHASE II/III TRIAL assessing trimodality therapy with or without combination of anti-PDL-1 (DURVALUMAB) or anti-pdl-1 plus anti-ctla-4 (TREMELIMUMAB) to treat patients with muscle-invasive bladder cancer.  

W. Kassouf

8:00 am  Meeting Adjourned